Atlas Logo
Longitudinal European Autism Project (LEAP)
BACK
Sample details

LEAP is a multi-site study that aims to identify biological markers for autism spectrum disorder (ASD). LEAP includes 437 participants with ASD and 300 control participants with typical development or mild intellectual disability. Participants were recruited and completed baseline assessments between 2014 and 2017. Follow-up assessments were conducted in two waves: Wave 2 took place approximately 12 to 24 months after baseline, and Wave 3 occurred approximately 7 to 10 years after Wave 2. Additionally, LEAP is enriching its cohort by recruiting individuals with autism and epilepsy and individuals with epilepsy only. LEAP also recruited a cohort of 53 twin pairs tested at one time point.

Study design
Cohort - accelerated

Number of participants at first data collection

437 (participants with ASD)

300 (control participants)

53 (twin pairs)

Age at first data collection

6 - 30 years (participants with ASD)

6 - 30 years (control participants)

6 - 26 years (twin pairs)

Participant year of birth

Varied (participants with ASD)

Varied (control participants)

Varied (twin pairs)

Participant sex
All

Representative sample at baseline?
No

Sample features

Adolescents
Adults
Autism Spectrum Disorder (ASD)
Children and young people
Typically developing
Dataset details
Loading map...

Countries

England, Germany, Italy, Netherlands, Sweden

Year of first data collection

2014

Primary Institutions

Campus Bio-Medico University of Rome (Università Campus Bio-Medico di Roma, UCBM)

Central Institute of Mental Health (Zentralinstitut für Seelische Gesundheit, CIMH)

Karolinska Institute (Karolinska Institutet, KI)

King's College London (KCL)

Radboud University Medical Center (Radboudumc)

Links

aims-2-trials.eu/leap-front-page/

doi.org/10.1186/s13229-017-0145-9

Funders

Autism Speaks

Autistica

European Federation of Pharmaceutical Industries and Associations (EFPIA)

European Union FP7 programmes

European Union Horizon 2020 Research and Innovation Program

Ongoing?
Yes

Data types collected

neuroImagingData
mentalHealthData
Quantitative data collection
  • Audio or visual recordings (e.g. of child behaviour, facial expressions)
  • Computer, paper or task testing (e.g. cognitive testing, theory of mind doll task, attention computer tasks)
  • Interview – face-to-face
  • Interview – phone
  • Passive electronic data collection (e.g. screen time, scroll speed)
  • Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
  • Self-report questionnaire – online
  • Wearable devices
Qualitative data collection
  • None
Neuroimaging data collection
  • Diffusion Tensor Imaging (DTI)
  • Electroencephalography (EEG)
  • Functional magnetic resonance imaging (fMRI)
  • Magnetic Resonance Imaging (MRI)
Linked or secondary data
  • None
Features

Engagement

  • Community engagement
  • Keywords

    Anxiety
    Attention Deficit Hyperactivity Disorder (ADHD)
    Autism and Autism-like conditions
    Biological samples/biospecimens
    Cognition
    Depression
    Health and wellbeing
    Medical history
    Neuroimaging
    Quality of life

    Consortia and dataset groups

    European Autism Interventions—A Multicentre Study for Developing New Medications (EU-AIMS)
    Contact us

    |

    FAQS

    |

    Privacy

    |

    © 2024 Louise Arseneault

    Platform by Delosis